Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting

Bibliographic Details
Main Authors:	Hong, Jihyung, Novick, Diego, Montgomery, William, Moneta, Maria Victoria, Dueñas, Héctor, Peng, Xiaomei, Haro, Josep Maria
Format:	Online
Language:	English
Published:	Dove Medical Press 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621215/

Similar Items

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
by: Novick, Diego, et al.
Published: (2016)

Should Unexplained Painful Physical Symptoms be Considered within the Spectrum of Depressive Symptoms?
by: Hong, Jihyung, et al.
Published: (2015)

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
by: Novick, Diego, et al.
Published: (2015)

Patient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in Central Europe and East Asia
by: Hong, Jihyung, et al.
Published: (2014)

Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?
by: Novick, Diego, et al.
Published: (2013)

Antidepressant medication treatment patterns in Asian patients with major depressive disorder
by: Novick, Diego, et al.
Published: (2015)

Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
by: Sheehan, David V., et al.
Published: (2016)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
by: Hong, Jihyung, et al.
Published: (2012)

Antinociceptive Effects of the Serotonin and Noradrenaline Reuptake Inhibitors Milnacipran and Duloxetine on Vincristine-Induced Neuropathic Pain Model in Mice
by: Katsuyama, Soh, et al.
Published: (2014)

Sex differences in the course of schizophrenia across diverse regions of the world
by: Novick, Diego, et al.
Published: (2016)

Pharmacovigilance of serotonin reuptake inhibitors
by: Darpan Kaur, et al.
Published: (2013-01-01)

Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients
by: Novick, Diego, et al.
Published: (2016)

Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia
by: Hong, Jihyung, et al.
Published: (2013)

Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis
by: Wozniak, Greta, et al.
Published: (2011)

The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring
by: Olivier, J. D. A., et al.
Published: (2013)

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†
by: Montgomery, Stuart A, et al.
Published: (2014)

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study
by: Novick, Diego, et al.
Published: (2015)

Predictors of duloxetine adherence and persistence in patients with fibromyalgia
by: Cui, Zhanglin, et al.
Published: (2012)

Effect of Serotonin Reuptake Inhibitors on Pulmonary Hemodynamics in Humans
by: Pleym, Hilde, et al.
Published: (2011)

Heart Rate Recovery and Selective Serotonin Reuptake Inhibitors
by: Cerit, Levent
Published: (2016)

Schizophrenia Outpatient Health Outcomes study: twelve-month findings
by: Novick, Diego, et al.
Published: (2012)

Serum Prolactin and Macroprolactin Levels among Outpatients with Major Depressive Disorder Following the Administration of Selective Serotonin-Reuptake Inhibitors: A Cross-Sectional Pilot Study
by: Kim, Sollip, et al.
Published: (2013)

Serotonin and Noradrenaline Reuptake Inhibitors Improve Micturition Control in Mice
by: Redaelli, Marco, et al.
Published: (2015)

Commentary: “Consistent Superiority of Selective Serotonin Reuptake Inhibitors Over Placebo in Reducing Depressed Mood in Patients with Major Depression”
by: Fried, Eiko I., et al.
Published: (2015)

Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression
by: Hieronymus, F, et al.
Published: (2016)

Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors‘ Behavioral and Neurochemical Effects
by: Munari, Leonardo, et al.
Published: (2015)

Effect of Selective Serotonin Reuptake Inhibitors and Immunomodulator on Cytokines Levels: An Alternative Therapy for Patients with Major Depressive Disorder
by: Hernandez, María Eugenia, et al.
Published: (2013)

Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study
by: Brugnoli, Roberto, et al.
Published: (2012)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
by: Ascher-Svanum, Haya, et al.
Published: (2014)

Real-world treatment patterns and opioid use in chronic low back pain patients initiating duloxetine versus standard of care
by: Andrews, Jeffrey Scott, et al.
Published: (2013)

Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder
by: Atake, Kiyokazu, et al.
Published: (2014)

Bioimpedance in monitoring of effects of selective serotonin reuptake inhibitor treatment
by: Alexeev, Vasiliy Grigorievich, et al.
Published: (2011)

Hyperprolactinemia and breast enlargement with serotonin reuptake inhibitor and olanzapine combination
by: Praharaj, Samir Kumar
Published: (2011)

Selective Serotonin Reuptake Inhibitors in Human Pregnancy: To Treat or Not to Treat?
by: Diav-Citrin, Orna, et al.
Published: (2012)

Are Selective Serotonin Reuptake Inhibitors a Secondary Cause of Low Bone Density?
by: Chau, Kim, et al.
Published: (2012)

Behavioral destabilization induced by the selective serotonin reuptake inhibitor fluoxetine
by: Kobayashi, Katsunori, et al.
Published: (2011)

Selective Serotonin Reuptake Inhibitors and Gastrointestinal Bleeding: A Case-Control Study
by: Carvajal, Alfonso, et al.
Published: (2011)

Prediction of Selective Serotonin Reuptake Inhibitor Response Using Diffusion-Weighted MRI
by: DeLorenzo, Christine, et al.
Published: (2013)

Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer
by: Ashbury, Janet E., et al.
Published: (2012)

The Necessity of Bone Densitometry for Patients Taking Selective Serotonin Reuptake Inhibitors
by: An, Ki-Yong, et al.
Published: (2013)